Kenneth R. Deans Jr.
South Carolina
Kenneth R. Deans Jr. is a Contributing Writer for The American Quorum. With 30+ years of leadership across healthcare, technology, and education, he brings an experienced, independent perspective to issues shaping America.
Tech
Apple Patches Two Actively Exploited Zero-Days Across iPhones, iPads and Macs
Healthcare
PACT Act Becomes Law, Expanding Toxic-Exposure Care and Benefits for Millions of Veterans
Tech
Biden Signs $52.7 Billion Semiconductor Push as CHIPS and Science Act Becomes Law
Healthcare
U.S. Declares Monkeypox a Public Health Emergency as Cases Exceed 6,600 and Vaccine Demand Strains Supply
Tech
Amazon Agrees to Buy Roomba Maker iRobot for $1.7 Billion, Deepening Its Push Into Connected Homes
Healthcare
HHS Proposes Restoring ACA Civil-Rights Protections for LGBTQ Patients, Reproductive Care and Language Access
Tech
House Passes CHIPS and Science Act 243-187 After 64-33 Senate Vote, Sending $52 Billion Semiconductor Push to Biden
Healthcare
New York Confirms First U.S. Polio Case Since 2013 as Unvaccinated Rockland County Adult Develops Paralysis
Tech
Amazon Agrees to Buy One Medical for $3.9 Billion, Expanding From Pharmacy and Telehealth Into Primary-Care Clinics
Healthcare
FDA Authorizes Novavax COVID-19 Vaccine for U.S. Adults, Adding First Protein-Based Option
Tech
Twitter Sues Musk to Enforce $44 Billion Deal, Asking Delaware Court to Order Closing at $54.20 a Share
Healthcare
FDA Lets Pharmacists Prescribe Paxlovid, Expanding Access With Kidney, Liver and Drug-Interaction Safeguards
Tech
Musk Moves to Terminate $44 Billion Twitter Deal, Alleging Data and Representation Breaches as Twitter Vows Enforcement
Healthcare
FDA Tells Vaccine Makers to Target Omicron BA.4 and BA.5 in Bivalent COVID-19 Boosters for Fall
Tech
Google Will Delete Location History for Abortion Clinics and Other Sensitive Sites After Roe Reversal
Healthcare
FDA Orders Juul Off U.S. Market, Citing Insufficient and Conflicting Toxicology Data
Tech
Twitter Board Recommends $44 Billion Musk Sale at $54.20 a Share as Bot Dispute Hangs Over Deal
423 stories